Skip to main content

Clinical Endocrine Oncology, 2nd Edition

Clinical Endocrine Oncology, 2nd Edition

Ian D. Hay (Editor), John A. H. Wass (Editor)

ISBN: 978-1-444-30023-9

Jan 2009, Wiley-Blackwell

664 pages

$307.99

Description

A truly comprehensive reference for the management of patients with endocrine cancer

The new edition of Clinical Endocrine Oncology has been fully revised and extended making it the most comprehensive and up-to-date reference available. Written and edited by leading international experts in the field, it sets the standard in multidisciplinary care for patients with endocrine tumors.

The book provides specific and detailed guidance on the basic, clinical, investigative and therapeutic processes required for the thorough evaluation of a patient with a tumor in an endocrine organ. The eighty-four chapters are arranged in seven parts:

• Endocrine Oncology and Therapeutic Options
• Thyroid and Parathyroid Tumors
• Pituitary and Hypothalamic Lesions
• Adrenal and Gonadal Tumors
• Neuroendocrine Tumors and the Clinical Syndromes
• Medical Syndromes and Endocrine Neoplasia
• Endocrine-responsive Tumors and Female Reproductive Hormone Therapy.

This authoritative and practical text will be an invaluable resource for all those working in the field, including endocrinologists, medical oncologists, surgeons, radiation therapists, interventional radiologists, specialist nurses, and clinical scientists.

John A.H. Wass is joined in this edition by a new editor, Ian D. Hay, Professor of Medicine and Endocrinology Research at the Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

List of Contributors.

Foreword.

Preface.

Endocrinology, the Hertz Brothers, and the History of Cancer.

Part I: Endocrine Oncology and Therapeutic Options:.

1 Structure and Development of the Endocrine System: John F. Morris (University of Oxford).

2 Epidemiology of Endocrine Tumors: Amanda Nicholson (University College London).

3 Inherited Cancers, Genes, and Chromosomes: Emma R. Woodward (Birmingham Women’s Hospital) and Eamonn R. Maher (Birmingham Women’s Hospital).

4 Hormones, Growth Factors, and Tumor Growth: Andrew G. Renehan (Christie Hospital NHS Trust, Manchester).

5 Genetic Counseling and Clinical Cancer Genetics: Lucy Side (Churchill Hospital, Oxford).

6 Prospects for Gene Therapy for Endocrine Malignancies: Christine Spitzweg (Ludwig-Maximilians-University Munich), Ian D. Hay (Mayo Clinic, Rochester, USA), and John C. Morris (Mayo Clinic College of Medicine, Rochester, USA).

7 Tumor Targeting: Mona Waterhouse (St Bartholomew’s Hospital, London) and Ashley B. Grossman (St Bartholomew’s Hospital, London).

8 Techniques in Radiation Medicine: P. Nicholas Plowman (St Bartholomew’s Hospital, London).

9 Interventional Radiology: Jane Phillips-Hughes (John Radcliffe Hospital, Oxford) and Philip Boardman (Churchill Hospital, Oxford).

10 Surgical Management of Endocrine Tumors: Gustavo G. Fernandez Ranvier (University of California, San Francisco) and Orlo H. Clark (University of California, San Francisco).

11 Endocrine Tumor Markers: Stefan K.G. Grebe (Mayo Clinic, Rochester).

12 General Management of Cancer Patients: Marcia Hall (Mount Vernon Cancer Centre, Middlesex).

Part II: Thyroid and Parathyroid Tumors:.

13 Assessment of Thyroid Neoplasia: Kristien Boelaert (Queen Elizabeth Hospital, Birmingham), Jayne A. Franklyn (University of Birmingham), and Michael Sheppard (University of Birmingham).

14 Thyroid and Parathyroid Imaging: Conor J. Heaney (Mayo School of Graduate Medical Education, Rochester, USA) and Gregory A. Wiseman (Mayo Clinic College of Medicine, Rochester, USA).

15 Pathogenesis of Thyroid Cancer: Jan Zedenius (Karolinska University Hospital, Stockholm) and Theodoros Foukakis (Karolinska University Hospital, Stockholm).

16 Papillary Thyroid Carcinoma: Ian D. Hay (Mayo Clinic, Rochester, USA).

17 Follicular Thyroid Carcinoma: Manisha H. Shah (The Ohio State University) and Matthew D. Ringel (The Ohio State University).

18 Anaplastic Thyroid Carcinoma: Richard T. Kloos (The Arthur G James Cancer Hospital and Solove Research Center, Columbus).

19 Thyroid Lymphoma: Christopher M. Nutting (Royal Marsden Hospital, London) and Kevin J. Harrington (Cancer Research UK Centre for Cell and Molecular Biology, London).

20 Radiation-induced Thyroid Tumors: David H. Sarne (University of Illinois at Chicago) and Arthur Schneider (University of Illinois at Chicago).

21 Parathyroid Adenomas and Hyperplasia: Bart L. Clarke (Mayo Clinic College of Medicine, Rochester).

22 Parathyroid Carcinoma: Göran Åkerström (University Hospital, Uppsala, Sweden), Per Hellman (University of Uppsala, Sweden), and Peyman Björklund (University of Uppsala, Sweden).

Part III: Pituitary and Hypothalamic Lesions:.

23 Molecular Pathogenesis of Pituitary Adenomas: Ines Donangelo (University of California Los Angeles) and Shlomo Melmed (University of California Los Angeles).

24 Functional Assessment of the Pituitary: John S. Bevan (Aberdeen Royal Infirmary).

25 Imaging of the Pituitary and Hypothalamus: James V. Byrne (John Radcliffe Hospital, Oxford).

26 Pathology of Tumors of the Pituitary: Eva Horvath (St. Michael’s Hospital, Toronto) and Kalman Kovacs (St. Michael’s Hospital, Toronto).

27 Surgery for Pituitary Tumors: Simon A. Cudlip (John Radcliffe Hospital, Oxford).

28 Pituitary Radiotherapy: P. Nicholas Plowman (St Bartholomew’s Hospital, London).

29 Prolactinomas: Mary P. Gillam (Northwestern University Feinberg School of Medicine, Chicago) and Mark E. Molitch (Northwestern University Feinberg School of Medicine, Chicago).

30 Acromegaly: John A.H. Wass (Churchill Hospital, Oxford).

31 Cushing’s Disease: John Newell-Price (University of Sheffield).

32 Non-functioning Pituitary Adenomas and Gonadotropinomas: Maarten O. van Aken (Erasmus Medical Center, Rotterdam), Aart Jan van der Lelij (Erasmus Medical Center, Rotterdam), and Steven W.J. Lamberts (Erasmus Medical Center, Rotterdam).

33 Thyrotropinomas: Paolo Beck-Peccoz (Fondazione Policlinico IRCCS, Milan) and Luca Persani (Istituto Auxologico Italiano IRCCS, Milan).

34 Pituitary Carcinoma: Olaf Ansorge (John Radcliffe Hospital, Oxford).

35 Pituitary Incidentalomas: Karin Bradley (Bristol Royal Infirmary).

36 Craniopharyngioma: Niki Karavitaki (Churchill Hospital, Oxford).

37 Benign Cysts: Rathke’s Cleft Cysts, Mucoceles, Arachnoid Cysts, and Dermoid and Epidermoid Cysts: Niki Karavitaki (Churchill Hospital, Oxford).

38 Hypothalamic Hamartomas and Gangliocytomas: Lawrence A. Frohman (University of Illinois at Chicago).

39 Cranial Ependymoma: Silvia Hofer (University Hospital Zürich) and Michael Brada (The Royal Marsden NHS Trust, London and Sutton).

40 Perisellar Tumors including Chordoma, Optic Nerve Glioma, Meningioma, Hemangiopericytoma, and Glomus Tumors: David Choi (The National Hospital for Neurology and Neurosurgery, London) and Alan Crockard (The National Hospital for Neurology and Neurosurgery, London).

41 Pineal Tumors: Germinomas and Non-germinomatous Germ Cell Tumors: Frank Saran (Royal Marsden NHS Foundation Trust, Sutton) and Sharon Peoples (Western General Hospital, Edinburgh).

42 Cavernous Sinus Hemangiomas: Mark E. Linskey (University of California).

43 Langerhans’ Cell Histiocytosis: Matthew F. Gorman (University of California), Michelle Hermiston (UCSF School of Medicine, San Francisco), and Katherine K. Matthay (UCSF School of Medicine, San Francisco).

44 Pituitary and Hypothalamic Sarcoidosis: Damian G. Morris (The Ipswich Hospital NHS Trust) and Shern L. Chew (St Bartholomew’s Hospital, London).

Part IV: Adrenal and Gonadal Tumors:.

45 Imaging of the Adrenal Glands: Anju Sahdev (St Bartholomew’s Hospital, London) and Rodney H. Reznek (Barts and The London School of Medicine and Dentistry).

46 Pheochromocytoma: Andrew Solomon (Royal Free Hospital, London) and Pierre Bouloux (Royal Free and University College Medical School, London).

47 Peripheral Neuroblastic Tumors: Bruno De Bernardi (Giannina Gaslini Children’s Hospital), Vito Pistoia (Giannina Gaslini Children’s Hospital), Claudio Gambini (Giannina Gaslini Children’s Hospital), and Claudio Granata (Giannina Gaslini Children’s Hospital).

48 Primary Hyperaldosteronism: Mark Sherlock (University of Birmingham) and Paul M. Stewart (University of Birmingham).

49 Adrenal Causes of Cushing’s Syndrome: John R. Lindsay (Altnagelvin Area Hospital, Londonderry) and A. Brew Atkinson (Royal Victoria Hospital, Belfast).

50 Adrenal Incidentalomas: Maria Verena Cicala (University of Padua), Pierantonio Conton (University of Padua), Anna Patalano (University of Padua), and Franco Mantero (University of Padua).

51 Androgen-secreting Tumors: Quirinius Barnor (University College London Hospitals), Tom R. Kurzawinski (University College London Hospitals), and Gerard S. Conway (University College London Hospitals).

52 Functional Ovarian Tumors: Nia Jane Taylor (The John Radcliffe Hospital, Oxford) and Niall Richard Moore (University of Oxford).

53 Endocrine Aspects of Ovarian Tumors: John H. Shepherd (Royal Marsden Hospital, London) and Lisa Wong (Royal Marsden Hospital, London).

54 Testicular Germ Cell Cancers: R. Timothy D. Oliver (St Bartholomew’s Hospital, London).

55 Neoplasia and Intersex States: Sabine E. Hannema (Juliana Children’s Hospital, The Hague) and Ieuan A. Hughes (University of Cambridge).

56 Gestational Trophoblastic Neoplasia: Tim Crook (Charing Cross Hospital) and Michael J. Seckl (Hammersmith Hospitals Campus of Imperial College London).

Part V: Neuroendocrine Tumors and the Clinical Syndromes:.

57 Classification of Neuroendocrine Tumors: Adeel Ansari (Hammersmith Hospital Campus, Imperial College London), Karim Meeran (Imperial College London), and Stephen R. Bloom (Imperial College London).

58 Imaging of Gastrointestinal Neuroendocrine Tumors: Andrew F. Scarsbrook (St James’s University Hospital) and Rachel R. Phillips (University of Oxford).

59 Insulinomas and Hypoglycemia: Adrian Vella (Mayo Clinic College of Medicine, Rochester, USA) and F. John Service (Mayo Clinic College of Medicine, Rochester, USA).

60 Gastrinomas (Zollinger–Ellison Syndrome): Matthew L. White (St. Joseph Mercy Hospital, Ann Arbor, Michigan) and Gerard M. Doherty (University of Michigan).

61 VIPomas: Vian Amber (Imperial College London) and Stephen R. Bloom (Imperial College London).

62 Glucagonomas: Niamh M. Martin (Imperial College London), Karim Meeran (Imperial College London), and Stephen R. Bloom (Imperial College London).

63 Somatostatinomas: John A.H. Wass (Churchill Hospital, Oxford).

64 Lung and Thymic Neuroendocrine Tumors: Dan Granberg (University Hospital, Uppsala, Sweden) and Kjell Öberg (University Hospital, Uppsala, Sweden).

65 Carcinoid Syndrome: Thorvardur R. Halfdanarson (Mayo Clinic College of Medicine, Rochester, USA) and Timothy J. Hobday (Mayo Clinic, Rochester, USA).

66 Appendiceal and Hindgut Carcinoids: Humphrey J.F. Hodgson (Royal Free and University College School of Medicine, London).

67 Chemotherapy for Neuroendocrine Tumors: Rebecca L. Bowen (St Bartholomew’s Hospital, London) and Maurice L. Slevin (St Bartholomew’s Hospital, London).

Part VI: Medical Syndromes and Endocrine Neoplasia:.

68 Multiple Endocrine Neoplasia Type 1 (MEN 1): Cornelis J.M. Lips (University Medical Center, Utrecht), Koen M.A. Dreijerink (University Medical Center, Utrecht), Gerlof D. Valk (University Medical Center, Utrecht), and Jo W.M. Höppener (University Medical Center Utrecht).

69 Medullary Thyroid Carcinoma and Associated Multiple Endocrine Neoplasia Type 2: Clive S. Grant (Mayo Clinic, USA).

70 von Hippel–Lindau Disease: Shern L. Chew (St Bartholomew’s Hospital, London) and Eamonn R. Maher (University of Birmingham School of Medicine).

71 Neurofibromatosis Type 1: Vincent M. Riccardi (The Neurofibromatosis Institute, California).

72 Carney Complex: Constantine A. Stratakis (National Institutes of Health, USA).

73 McCune–Albright Syndrome: William F. Schwindinger (Geisinger Clinic Danville, USA) and Michael A. Levine (Cleveland Clinic Children’s Hospital).

74 Cowden Syndrome: Ingrid Witters (University Hospital of Leuven, Belgium) and Jean-Pierre Fryns (University Hospital of Leuven).

75 Paraneoplastic Syndromes: David William Ray (University of Manchester).

76 Syndrome of Inappropriate Antidiuretic Hormone Secretion: Rachel K. Crowley (Beaumont Hospital, Dublin) and Chris Thompson (Beaumont Hospital).

77 Hypercalcemia of Malignancy: Gregory R. Mundy (Vanderbilt Center for Bone Biology, USA), Babatunde Oyajobi (University of Texas), Susan Padalecki (University of Texas),.

and Julie A. Sterling (Vanderbilt University, USA).

78 Syndrome of Ectopic ACTH Secretion: Marie-Laure Raffin-Sanson (Hôpital Ambroise Paré, Boulogne, France), Hélène Fierrard (Hôpital Ambroise Paré, Boulogne, France),.

and Xavier Bertagna (Université Paris Descartes, France).

79 Insulin-like Growth Factors and Tumor Hypoglycemia: Robert C. Baxter (University of Sydney).

80 Metastatic and Other Extraneous Neoplasms in Endocrine Organs: Ian D. Buley (Torbay Hospital, UK).

81 Endocrine Late Effects of Cancer Therapy: Robert D. Murray (Leeds Teaching Hospitals NHS Trust).

Part 7: Endocrine-responsive Tumors and Female Reproductive Hormone Therapy.

82 Endocrine-responsive Tumors: Prostate Cancer: Sarah Ngan (Imperial College London), Ana Arance (Hammersmith Hospital, London), and Jonathan Waxman (Imperial College London).

83 Endocrine Therapy in Breast Cancer Management: Andrew M. Wardley (Christie Hospital, Manchester).

84 Female Reproductive Hormone Therapy: Risks and Benefits: Toral Gathani (University of Oxford), Jane Green (University of Oxford), and Valerie Beral (University of Oxford).

Appendix of conversion units.

Index.

Color plate section

“I recommend the book for physicians who see diagnose and treat patients with endocrine tumors It provides a broad strong base of knowledge and a good foundation for further investigation of the treatment options for these tumors.” (New England Journal of Medicine, April 2009)

“The new edition of Clinical Endocrine Oncology has been fully revised and extended making it the most comprehensive and up-to-date reference available. Written and edited by leading international experts in the field, it sets the standard in multidisciplinary care for patients with endocrine tumors. This authoritative and practical text will be an invaluable resource for all those working in the field … .Because so much has changed since the first edition was published 11 years ago, a second edition is warranted.” (Doody's Book Reviews, October 2008)

● The most comprehensive text in the field
● Provides specific and detailed guidance on basic, clinical, investigative and therapeutic processes required for the thorough evaluation of a patient with an endocrine tumor
● Includes a new co-editor, Ian D. Hay, Professor of Medicine at the Mayo Clinic
● More emphasis on evidence-based medicine
● Contains several new chapters, including the role of hormones in cancer cachexia